Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dingell Says Lab Closures “Frightening,” FDA District Chief Expects Problems

This article was originally published in The Tan Sheet

Executive Summary

House Energy and Commerce leaders say FDA's plan to close several labs - including its only facility testing for radiological contaminants - is a threat to national security, while an FDA district chief says problems are likely to hinder the agency's work early in the planned reorganization

You may also be interested in...



Drug Firms Model Ensuring Import Safety; China’s Inconsistencies Worry FDA

Firms using Chinese imports to make dietary supplements and other products can look to drug firms for lessons on ensuring the safety of raw materials from China, where adherence to food and drug production regulations remains inconsistent, current and former FDA executives tell a Senate panel

Drug Firms Model Ensuring Import Safety; China’s Inconsistencies Worry FDA

Firms using Chinese imports to make dietary supplements and other products can look to drug firms for lessons on ensuring the safety of raw materials from China, where adherence to food and drug production regulations remains inconsistent, current and former FDA executives tell a Senate panel

Drug Firms Model Ensuring Import Safety; China’s Inconsistencies Worry FDA

Firms using Chinese imports to make dietary supplements and other products can look to drug firms for lessons on ensuring the safety of raw materials from China, where adherence to food and drug production regulations remains inconsistent, current and former FDA executives tell a Senate panel

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel